Patritumab deruxtecan has Breakthrough Therapy Designation for EGFR-mutated locally advanced or metastatic non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Ifinatamab deruxtecan is in Phase II for previously treated extensive-stage small cell lung cancer, and raludotatug deruxtecan is in a first-in-human Phase I trial for ovarian cancer.
In the top October M&A by deal value, Roche entered into a definitive agreement with Roivant to acquire its Telavant...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?